Dermatitis News and Research

Latest Dermatitis News and Research

Oral toxicity is frequent limitation of mTOR therapy

Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.

4 Feb 2013

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

The increasing incidence of allergic skin diseases, and the accompanying economic burden and heightened risk of developing other allergic conditions, have spurred researchers to look for better ways to control these immune system-based disorders.

1 Feb 2013

New insight into eczema’s itch

Research shows that innate lymphoid cells accumulate in active eczema lesions and may contribute to disease progression.

31 Jan 2013

Selenium supplements do not reduce risk of developing heart disease according to current evidence

A systematic review published today in The Cochrane Library finds that in well-nourished adults current evidence does not support selenium for preventing heart disease.

31 Jan 2013

Asthma linked to atopic dermatitis persistence

Asthma is associated with rash persistence in children with atopic dermatitis, US researchers report.

28 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 will be presented in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC.

23 Jan 2013

Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

Itch was actually defined by a German physician more than 350 years ago. His name was Samuel Hafenreffer. He defined itch as an unpleasant sensation that makes people want to scratch. You probably think this is a very simple definition but itch is really a very complex sensory modality.

21 Jan 2013

People most often visit doctors because of skin issues, joint disorders and back pain

A new Mayo Clinic Proceedings study shows that people most often visit their health care providers because of skin issues, joint disorders and back pain. Findings may help researchers focus efforts to determine better ways to prevent and treat these conditions in large groups of people.

17 Jan 2013

Susceptibility genes for bovine digital dermatitis found

Researchers have identified genetic variants that influence susceptibility to bovine digital dermatitis, an infectious condition that causes lameness of the hindfoot.

9 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Brake for skin inflammation discovered

The absence of a protein called Ctip2 in the skin allows increased levels of T-helper 2 cytokines and may have a role in conditions such as atopic dermatitis, research in mice suggests.

4 Jan 2013

Pergamum’s DPK-060 Phase II trial on acute external otitis meets primary end-point

Pergamum AB announced today that the primary end-point was met in the randomized Phase II trial of DPK-060 for treatment of acute external otitis.

21 Dec 2012

Easy ways to prevent dry skin

What do cleansers, alcohol and coffee have in common? They are the worst enemies of your skin during winter, sucking out the moisture from your skin and making it extremely dry and itchy.

11 Dec 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Allergies common in ADHD, tic disorder patients

A significant number of people with attention deficit/hyperactivity disorder and tic disorder also have one or more allergic diseases such as asthma or atopic dermatitis, show study results.

23 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

General guidelines to understand allergic skin conditions

Winter months can bring on the itch as cold weather and indoor heat dry out the skin. It's possible, suggests Chicago allergist, Brian Rotskoff, MD of Clarity Allergy Center, that your winter itch could be caused by more than just the weather. For some people itchy, dry skin is just that, but for others it can be a symptom of atopic dermatitis (eczema), contact dermatitis, or hives (urticaria).

16 Nov 2012

Smoking affects development of peripheral allergy-relevant stem cells in the blood

Environmental contaminants, such as smoking, are harmful to the human organism in relation to the occurrence of allergies. This is known. Until now, researchers had never investigated whether and to what extent environmental contaminants also affect allergy-relevant stem cells.

15 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Dermatitis News and Research

Latest Dermatitis News and Research

Oral toxicity is frequent limitation of mTOR therapy

Innate lymphoid cells may be new therapeutic target in treating atopic dermatitis

New insight into eczema’s itch

Selenium supplements do not reduce risk of developing heart disease according to current evidence

Asthma linked to atopic dermatitis persistence

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Data from Provectus' PV-10 pre-clinical study on melanoma to be presented at AACR meeting

Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

People most often visit doctors because of skin issues, joint disorders and back pain

Susceptibility genes for bovine digital dermatitis found

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Brake for skin inflammation discovered

Pergamum’s DPK-060 Phase II trial on acute external otitis meets primary end-point

Easy ways to prevent dry skin

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Allergies common in ADHD, tic disorder patients

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

General guidelines to understand allergic skin conditions

Smoking affects development of peripheral allergy-relevant stem cells in the blood

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Dermatitis News and Research

Latest Dermatitis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in